Related Experiment Video
Updated: Nov 25, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
11.5K
[Research progress of prognostic biomarkers in diffuse large B-cell lymphoma]
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|December 20, 2020
Summary
New prognostic biomarkers are crucial for diffuse large B-cell lymphoma (DLBCL) treatment. This review covers hematological, genetic, and tumor microenvironment factors to guide precision medicine for DLBCL.
Area of Science:
- Oncology
- Hematology
- Biomarker Discovery
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a complex cancer with varied patient outcomes.
- Existing prognostic models for DLBCL are becoming less effective due to new therapies.
- Understanding DLBCL biology is advancing rapidly with new technologies.
Purpose of the Study:
- To review and summarize prognostic biomarkers for DLBCL.
- To explore biomarkers from hematological, genetic, and tumor microenvironment factors.
- To provide a basis for precision treatment strategies in DLBCL.
Main Methods:
- Literature review of prognostic biomarkers in DLBCL.
- Analysis of hematological factors.
- Evaluation of genetic markers.
- Assessment of tumor microenvironment components.
Main Results:
- Identified numerous emerging biomarkers for DLBCL.
- Highlighted the roles of hematological, genetic, and microenvironmental factors.
- Emphasized the need for updated prognostic tools.
Conclusions:
- New biomarkers are essential for accurate DLBCL prognosis.
- These biomarkers can refine treatment strategies and improve patient outcomes.
- Further research into these factors will support precision medicine for DLBCL.
